Drug Controller General of India (DCGI) has given permission for the drug 2-deoxy-D-glucose (2-DG) emergency use as an adjunct therapy in moderate to severe COVID-19 cases. The Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of DRDO, in collaboration with Dr. Reddy's Laboratories, Hyderabad, has developed this drug.
The third phase clinical trials of the drug are currently going on, and the initial trials have reportedly shown that it helps in the faster recovery of hospitalized patients and reduces supplemental oxygen dependence. The drug will be available in powder form in a sachet.
It needs to be taken orally by dissolving in water. Moreover, the drug is a generic molecule and analogue of glucose. It easily produced and can be quickly made available across the country. This drug can be a game-changer for the country which the COVID Second Wave has severely battered. The nation is continuously clocking over Four Lakh cases per day.
An anti-COVID-19 therapeutic application of the drug 2-deoxy-D-glucose (2-DG) has been developed by INMAS, a lab of DRDO, in collaboration with Dr Reddy’s Laboratories, Hyderabad. The drug will help in faster recovery of Covid-19 patients. https://t.co/HBKdAnZCCP pic.twitter.com/8D6TDdcoI7
— DRDO (@DRDO_India) May 8, 2021